The efficient and effective selection of appropriate plants for investigative purposes in a drug discovery program is of crucial importance for a successful outcome. A variety of approaches have been used by researches with varying levels of success. A variety of different approaches to plant selection are discussed, including the ethnomedicinal approach, some ecological approaches and the use of combinatorial and computational methodologies.
Introduction

Figure 1: Outline of Possible Approaches to the Discovery of New Drug Leads
A review of the types of drugs used to treat the wide spectrum of both infectious and non-infectious diseases serves to highlight the essential role played by plant, marine and microorganism-based secondary metabolites. Undoubtedly natural sources still represent a rich untapped resource for the discovery of new drugs. The present lack of funding for natural products research in some parts of the world where this type of research is seen as 'fishing' and low citation numbers and relatively low impact factors of journals in the field make the area of research unpopular by some funding agencies and university administrators. On the other hand, in parts of the world where numbers of publications, and not necessary quality, is used as an indicator of academic success, often the rush to publish (and to publish as many papers as possible from one plant), and lack of appropriate screening facilities hinders the thorough evaluation of compounds produced for potential pharmacological activity. Faced with such extensive biodiversity and limited resources, the choice of where to most effectively focus one's attention becomes crucial. The choice may be guided by past successes or perhaps by current innovations with potential to deliver future results.
The success of natural product research has been well reviewed by many, including four thorough analyses of the contribution of natural products to approved therapeutic agents by Newman, Cragg and Snader in 1997 and 2003 [1, 2] and by Newman and Cragg in 2007 and 2012 [3, 4] . During the period 1981 to 2010, 54% of all new approved drugs came from natural sources. Of these 4% were natural products, 22%
were derived from natural products, 13% were produced by total synthesis but the active chromophore was a natural product and 15 % were from a biological source such as a large protein or peptide isolated from an organism or cell line [4] . If only the small-molecule approved drugs are considered, then 6% were natural products, 28% were derived from natural products and 16% were produced by total synthesis, where the pharmacophore was based on a natural product [4] .
The development of drugs from natural products comes at a significant time and financial cost. It is estimated that on average the cost of getting a drug to market is in excess of $ 1 billion if post approval Phase IV costs and costs linked to approval on non US markets are taken into account [5] . The National Cancer Institute (NCI) screened around 200 000 extracts between 1955 and 1980 with limited success [6] .
This led to a reduction in focus on random screening until 1986, when, with the improvement of screening methods, the NCI started screening again. By 1995, 40 000 extracts had been prepared and 18 000 screened for activity. The success rate was about 1% [6] . In contrast, however, combinatorial chemistry has resulted in only one approved drug (Sorafenib) in the public domain in the time period until 2010 [4].
This does not, however, take away from the fact that combinatorial chemistry is highly effective as a tool for structural optimization of an active chemical skeleton [4] . Comparing compounds prepared by people to those produced by plants, the most striking difference is one of complexity. Natural sources use enzymes to bring about chemical transformations, enabling very specific structural changes to be made to specific sites in a stereospecific manner resulting in a complex molecule [6] . Being able to tap into this source of chemical diversity in a meaningful and effective way is crucial to successful drug development.
The factors influencing the selection of marine or microbial samples for evaluation are, in most cases, different from those directing the choice of plant material. The marine environment provides a vast, largely untapped, source of biodiversity. One of the primary challenges facing sample selection in a marine setting is one of accessibility -your choice is often decided by what you can physically access and, as such, work is more frequently carried out on organisms living close to the shore [7] .
Sampling techniques often require specialized equipment and in many cases very small quantities of active compound are obtained requiring nanomolar structure determination [7] .
With approximately half of the 20 best-selling non-protein drugs based on natural products and with almost all of the currently used natural products being of terrestrial origin (Harvey 2000, in Monaster and Luesch 2011) [7] , the identification of good methods to improve the successful selection of promising plant material remains crucial. In the light of the significant differences in the challenges facing the choice of marine or microbial material as opposed to plant material for study, this paper will restrict its comments to the selection of plant material.
Success in identifying a new biologically active plant-based natural product can be influenced firstly by a clever choice of plant to investigate or secondly by how quickly and effectively a random selection of plant extracts can be screened. Each of these approaches has produced a level of success and many of the methods employed in plant selection are based on one or the other system. The huge cost involved in both time and resources to screen vast numbers of randomly selected extracts, with the small success rate, has led many investigators to advocate selection based on various non-random approaches [8] . The various approaches that will be discussed are outlined in figure 1.
The ethnomedicinal approach
The ethnomedicinal approach has resulted in a number of success stories. The 19 th century saw scientists starting to isolate the active principle from medicinally used plants -the first notable success being quinine from Chinchona bark by Caventou and Pelletier [9] . Other pre-world war 2 successes include morphine and codeine from the opium poppy, digoxin from Digitalis leaves and atropine (produced from (-)-hyoscyamine) from Solanaceae species [9] . Tiotropium is currently being used to treat chronic obstructive pulmonary disease and is a derivative of atropine [10] . More recent years have seen cancer therapy impacted by natural products. The most notable perhaps, being the derivatives of camptothecan and the diterpene, taxol.
Camptothecan was isolated from Campotheca acuminate Decne., a tree widely used in Chinese traditional medicine, which resulted in its inclusion in the National Cancer Institute screening program [10] . In contrast, several samples of Taxus brevifolia were randomly collected for analysis by the National Cancer Institute. The discovery of taxol was seen as serendipitous, but the tree has been used by West-American Indian groups for stomach complaints among other things and the Tsimshian (from British Columbia) use it to treat cancer [10] .
Galanthamine, isolated from the Russian species Galanthus woronowii Losinsk. Was discovered through an ethnobotanical lead and is currently being used to treat Alzheimer's disease [10] .
The decision to investigate a particular plant species is very often determined by the fact that the plant is already being used for some purpose, possibly medicinally or as an insect repellent or for some cultural purpose. This would constitute an ethnobotanical approach to plant selection and would apply to a vast number of phytochemical investigations. The testing of the plant extracts and any isolated [11] . Two important issues need to be addressed in regard to the ethnomedicinal approach to plant selection. Firstly the rights of the country of origin with respect to any drugs discovered need to be protected, as outlined in the United Nations Convention on Biological Diversity [12] . Secondly the quality of any ethnopharmacological field studies carried out prior to plant selection is important, and may have an impact on the success of the research [13] . Thorough ethnopharmacological field studies can lay a vital platform from which the phytochemical investigation of a plant species can be launched. Comprehensive field studies and the establishment of ethnomedicinal databases can provide valuable resources to those wishing to select promising plants for study.
Statistical analysis of the sometimes vast databases of medicinally used plants has been successfully used to identify families of plants that are over-or underused by traditional practitioners. Regressional analysis [20] , contingency table and binomial analyses [21] as well as Baysian and Imprecise Dirichlet Model (IDM) approaches [22, 23] have been used. Regression analysis has been used to analyse the SANBI Medlist Database of southern African medicinally used plants [20] , contingency table and binomial analyses to investigate the Ecuadorian Shuar medicinal flora [21] and the medicinal flora of Campania, Italy has been analysed by the Baysian, binomial and IDM methods [22, 23] . These studies all demonstrated a clear bias for particular families in each of the regions investigated and, as such, could be used to guide the choice of plants to be studied.
The value of the ethnomedicinal approach to plant selection may be determined by its successes and failures. A small number of studies will be mentioned here in this regard. Khafagi Over the whole range of tests, the randomly selected 'collections' were 3% more likely to give a positive result than those ethnomedicinally selected. With 'samples', the ethnomedicinally selected extracts were 6% more likely to give a positive result [25] .
A large number of papers have been published reporting positive activity over a wide range of tests for plant extracts chosen using ethnomedicinal criteria. In many cases the active principal is isolated and identified, but the value is mostly in verifying the efficacy of the plant rather than the isolated active compound being developed further into a registered drug. The ethnomedicinal approach has successfully been used by the researchers at Shaman Pharmaceuticals to verify the use of Cryptolepsis sanguinolenta (Lindl.) as a treatment for type II diabetes as well as a basis for the isolation of the active component, the alkaloid, cryptolepine [26, 27] . C. sanguinolenta is used by traditional healers in Ghana to treat symptoms of type II diabetes, including fungal infections, pain and inflammation [26] .
Cryptolepine and its hydrochloride salt possess a range of well-documented biological activities, including antimicrobial, antibacterial, antiinflammatory, antihypertensive, antipyretic, antimuscarinic, antithrombotic, noradrenergic receptor antagonistic and vasodilative properties as well as being used as an effective antimalarial agent [26] .
Both the dichloromethane and hot water extracts of the ground roots of C. sanguinolenta demonstrated the ability to lower blood glucose in a non-insulindependent diabetes mellitus mouse model. In vivo-guided fractionation, using the same model resulted in the isolation of cryptolepine as the active ingredient [26, 27] .
A small study was conducted using 20 women newly diagnosed with type II diabetes.
Plasma glucose levels decreased immediately after administration of the plant extract (ground roots boiled in water, 20mL of extract given four times a day, equivalent to 0.11 mg/kg body weight/day). Mean glucose level of 16.6 mmol/L reduced to 4 mmol/L) [27] . Such studies demonstrate the possibilities of using the ethnomedicinal approach, both in verifying the use of a particular plant to treat a particular disease, but also in the isolation of the active ingredient. Haddad et al. [28] and artemisinin and its derivatives) [29] . Of the 700 taxa used to treat malaria and/or fever, 134 were selected using weighted criteria (the taxon's association with malaria, documented antiplasmodial potential of the plant family, its use by traditional healers, whether it occurred in a malaria-endemic area and its popularity in the local plant markets). This resulted in 49% of the plant extracts tested showing good activity (IC50< or = 10g/mL) and 17% being highly active (IC50< or = 5g/mL) [29] .
A further application of the ethnomedicinal approach is to make cross-cultural comparisons of plant families or genera used for various diseases. Saslis-Lagoudakis et al. [30] compared the literature available on plant use for medicinal purposes across three distinct regions; Nepal, New Zealand and the Cape of South Africa.
Regressional and binomial analyses were performed at a family level and resulted in the identification of several 'hot' families (Anacardiaceae, Asteraceae, Convolvulaceae, Clusiaceae, Cucurbitaceae, Euphorbiaceae, Geraniaceae, Lamiaceae, Malvaceae, Rubiaceae, Sapindaceae, Sapotaceae and Solanaceae). In spite of many significant differences found across these three regions, the similarities may serve to indicate an underlying biological activity in the commonly used families.
The prevention of chronic non-communicable diseases (like cancer, heart disease, Sparrm. are all used to facilitate labour in pregnant women. Each was extracted using water modified supercritical carbon dioxide and the extracts were found to exhibit uterotonic activity. By coupling a biological detector to the supercritical fluid extractor, active fractions could be immediately detected and active components could be isolated. In the case of Grewia occidentalis, the extraction vessel was coupled directly to the bioassay being used (a muscle bath with guinea pig uterine muscle attached to a recorder). The sample was extracted sequentially at three different pressures, 200, 300 and 400 atmospheres, with the 300 atmosphere extract immediately being identified as the most active [36] . The development of techniques that can be used to selectively extract specific compounds of interest are of huge benefit to ethnomedicinal plant studies and have the potential to increase the rate at which potentially interesting plants can be studied.
The ecological approach
Another non-random method of plant selection involves various ecologically based approaches. Different authors have considered different aspects of the ecological argument, including the relationship between biodiversity and chemodiversity [8], the apparency theory [38, 39] , the life-strategy theory [40] , chemical defenses and herbivory [41] , animal behavior [42] and phylogenetic trends [43, 44] .
Ramesha et al. Zhu et al. [43] conducted a phylogenic study of the naturally-derived drugs approved between 1991 and 2010. It was found that drug-productive species were clustered in specific phylogenic space. It was suggested that a focus on untapped species belonging to already drug-productive families and clusters would increase the likelihood of discovering new useful bioactive compounds. Saslis-Lagoudakis et al. [44] have linked ethnomedicinal use of the plants belonging to the genus Pterocarpus with specific nodes in the phylogeny. They showed that species used to treat specific diseases, like malaria, tend to be phylogenetically clumped. It could be assumed that closely related species would share a similar biochemistry and an understanding of phylogenetic relationships between plant species could facilitate plant selection for study.
In order to defend themselves against herbivorous attack, plants have adopted a number of different strategies. The apparency theory divides plants into two groups; those with a short life-cycle (herbs, annuals) that need to invest in small amounts of toxic chemicals to defend themselves (non-apparent) and those with a long life-cycle (apparent) who invest in quantitative, less toxic chemicals to reduce their digestibility [38] . This would suggest that traditional practitioners, as well as those prospecting for new bioactive compounds, should prefer non-apparent plants. de Almeida et al. [38] [39] investigated whether the apparency theory could predict traditional medicinal practitioners' choice of plants in the Caatinga and Atlantic Forest regions of northeast Brazil. Neither habitat nor life-strategy were good predictors of phytochemical composition or plant selection in this region. Albuquerque et al. [41] have considered both the apparency theory together with the resource-availability hypothesis. In a resource-rich area, plants tend to be fast growing and tend to invest to eat the bark and seeds, which have no nutritional value and are bitter in taste [42] .
The petroleum extract of Khaya anthotheca showed good activity against Plasmodium falciparum K1 (IC50 = 0.955g/mL) and Trypanosoma brucei rhodesiense STIB 900 (IC50 = 5.72g/mL). It would appear that in addition to there being evidence for the effectiveness of these plants as used by traditional healers, that the chimpanzees and baboons were using the seeds and bark to self-medicate [42] .
Metabolomics
Metabolomics is the study of the 'global metabolite profile' in a system under a given set of conditions' [45] . While metabolomics does not help with the initial choice of plant to be studied, it can help with the rapid analysis of a plant extract and can give a good indication of the active constituents present in a particular extract.
Metabolomics allows for the profiling of the entire metabolome or of specific fractions thereof before testing for biological activity. The concentrations and characteristics of the chemical constituents can be determined and statistical analysis (principal component analysis or partial least squares regression analysis) used to link compounds with physiological activity [46] . A problem commonly encountered with bioassay-guided fractionation is the loss of activity during fractionation. An extract may contain a large amount of only moderately active compounds and so appear to be very active or it may contain very small amounts of highly active compounds.
Synergistic interactions also need to be considered under such circumstances [47] .
The aim of metabolomics is to assess a complex mixture and in so doing allow for the identification of biologically active constituents without first isolating the compound involved [47] .
Metabolomics has proved useful in the analysis of the active constituents of herbal medicines. For example, Iino et al. [48] have used capillary electrophoresis time of flight mass spectrometry (CE-TOFMS) to analyse Toki-Shakuyaku-San, a Chinese medicine used for gynaecological and obstetric conditions. They were able to identify 737 ± 183.1 (average± standard deviation) metabolite-derived features, of which 119 metabolites were identified [48] . The strength of the metabolomic approach when studying herbal medicines, is that it allows for the identification of all the compounds contributing to the medicinal effect of the plant and takes into account any synergism involved [49] .
Albrecht et al. [50] have used liquid chromatography mass spectrometry (LC-MS) followed by principal component analysis and orthogonal least squares discriminant analysis to profile and distinguish between Sutherlandia frutescens plants growing in different regions of South Africa. Clear differences in the metabolite profile were seen with implications for those in the herbal products industry utilizing Sutherlandia frutescens [50] .
Computational methods: virtual screening and reverse pharmacognosy
Virtual screening (VS) makes use of the availability of large compound libraries generated by combinatorial and high throughput chemistry to select a small number of likely candidates for experimental testing [51] . Virtual screening can follow one or both of two general strategies: ligand-based virtual screening or structure-based virtual screening [51] . Ligand-based VS makes use of structural and biological activity information from known active compounds to select likely compounds for further testing. Structure-based VS relies on knowledge of the 3-D structure of a molecule and uses techniques such as molecular docking (finding the best position and orientation of a compound within a binding site) to determine possible activity.
With sufficient information about the activity and the 3-D structure of a compound, both techniques can be used and the likelihood of a hit increases substantially [51] .
The effectiveness of VS can sometimes be compromised by the number of approximations and assumptions that need to be made but still in some cases substantially (100-fold to 1000-fold) higher hit rates than high throughput screening have been noted [51] . Virtual screening techniques transform chemical databases from storage banks of compounds to useful tools in the drug discovery process and allow all the work already done and recorded to be fully exploited [52] .
Decades of work in the field of pharmacognosy have resulted in a vast library of natural products, many of which have undergone only limited testing. Reverse pharmacognosy aims to find new biological targets for natural products by either virtual or real screening and then to link these findings to either the original or another potential plant source [53] . This inverse method starts with the molecule and ends with the plant source. This technique allows for the discovery of new biological activities from known natural compounds [54] . If a compound, available in large quantities from a renewable plant source is found to be active, both the use of the plant by local peoples is verified as well as the potential exploitation of the plant as a resource for development in a local community could be realized [55] . The research team at Greenpharma (France) have demonstrated the success of this technique with compounds like -viniferin (anti-inflammatory properties) [53] , Merazin (COX-1, COX-2 and PPAR activity) [55] and honokiol (modulation of testosterone levels) [56] and the details of the technique have been well reviewed [54] .
Conclusion
All of the approaches discussed above have shown some success in the identification of plants containing biologically active compounds. This success has not often led to the full development of a new commercial drug. The improvement in high throughput screening techniques and the use of virtual screening methods to identify potential hits should be exploited fully to increase the likelihood of success. Good collaboration between botanists, local traditional healers, chemists and pharmaceutical companies to ensure that potential hits are fully exploited is essential for progress. The high cost of drug development from natural sources necessitates clever approaches in the initial discovery phase. Utilizing a range of non-random approaches to plant choice can facilitate this, as can quicker and more effective methods of screening for activity. A fuller application of the work already done in natural products, via processes like reverse pharmacognosy, can help to open up further avenues of potential success.
